USA FDA Allows BioCancell to Commence Phase I/IIa Ovarian and Pancreatic Clinical Trials
News Jan 20, 2009
Tikcro Technologies Ltd. has announced that BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company, had received approval from the US Food and Drug Authority (FDA) to commence Phase I/IIa clinical trials in patients suffering from ovarian and pancreatic cancer, with the primary purpose of measuring the safety and primary efficiency of the BC-819 drug in a series of dose escalations.
The trials are planned to begin in medical centers in Israel and in the USA as soon as local regulatory approvals and agreements with the medical centers are concluded. Tikcro holds shares, warrants and convertible debt of Biocancell as previously detailed in our SEC filings.
For ovarian cancer, BC-819 will be administered intraperitoneally to 12 patients. Each patient will receive nine weekly treatments. The trial follows a compassionate use trial conducted in Israel with a patient suffering from ovarian cancer characterized by intra-peritoneal distribution of metastases and ascites after the failure of conventional chemotherapy treatment.
The results of the trial show that the drug caused no serious adverse events (SAE's) at any dosage, and that a decrease of 50% in the ovarian cancer marker protein CA-125 in the patient's blood was measured, as well as a significant decrease in the number of cancerous cells in the ascites, and reports of a clinical improvement in the patient's condition. The patient's quality of life was increased during the course of the treatment.
For pancreatic cancer, BC-819 will be administered intratumorally to 6-9 patients. Each patient will receive a total of four treatments over the course of two weeks. The Virginia Biosciences Development Center is BioCancell's USA partner for conducting this trial.
The trial follows pre-clinical studies that showed that when a group of hamsters was treated with BC-819 and compared to a control group, primary pancreatic tumor volume in the treated group was significantly reduced (50%) as compared with those in the control group, and that tumor growth progression (TGP) was significantly reduced in the treated group as compared with the control group. In addition, it was shown that one third of the treated group showed metastases, compared to 100% of the control group.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE